Management of Skin Toxicity Related to the Use of ImatinibMesylate (STI571, Glivec™) for Advanced Stage GastrointestinalStromal Tumours

[摘要] Skin toxicity is a common side-effect of treatment with imatinib mesylate (STI571, Glivec™) in advanced gastrointestinalstromal tumours (GIST) and chronic myeloid leukaemia. The optimal duration of treatment with imatinib mesylate inGIST has not yet been established, as durable remissions have been observed in patients. It is, therefore, important todevelop strategies to deal with common side-effects of what may be a long-term treatment. Here we report the case of apatient with advanced GIST who developed a cutaneous drug reaction secondary to imatinib mesylate and the variousmanagement options that may be employed depending upon the severity of the toxicity. The case and literature arediscussed.

[学科分类] 肿瘤学